ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO847

Chemokine Receptor 8 in Peripheral Blood Mononuclear Cells Can Be a Novel Diagnostic Biomarker for ANCA-Negative ANCA-Associated Vasculitis

Session Information

Category: Glomerular Diseases

  • 1202 Glomerular Diseases: Immunology and Inflammation

Authors

  • Mashiko, Shigeto, Japan Community Health Care Organization Sendai Hospital, Sendai, Japan
  • Sanada, Satoru, Japan Community Health Care Organization Sendai Hospital, Sendai, Japan
  • Sato, Mitsuhiro, Japan Community Health Care Organization Sendai Hospital, Sendai, Japan
  • Sato, Toshinobu, Japan Community Health Care Organization Sendai Hospital, Sendai, Japan
  • Taguma, Yoshio, Japan Community Health Care Organization Sendai Hospital, Sendai, Japan
Background

Diagnosis of antineutrophil cytoplasmic autoantibodies associated vasculitis (ANCA-associated vasculitis; AAV) is based on clinical and histologic features with elevated serum ANCA levels, however, not all cases show ANCA positive. In such cases, diagnosis of AAV without histological examination is quite difficult. We have found that the chemokine receptor 8 (CCR8) level in peripheral blood mononuclear cells correlates with activity of MPO-ANCA positive AAV; CCR8 is upregulated both in mRNA and protein levels, which was reported in the previous meeting. In this study, we extended our research of CCR8 levels in ANCA-negative AAV.

Methods

Peripheral blood mononuclear cells were collected from 81 patients representing rapidly progressive glomerulonephritis on their initial visit. Participants were categorized as ANCA-positive AAV, immune complex small vessel vasculitis, vasculitis associated with systemic disease, and ANCA-negative AAV according to Chapel Hill consensus conference criteria. CCR8 gene expression levels in each group were assessed retrospectively.

Results

CCR8 gene expression levels were significantly higher in patients with ANCA-negative AAV compared to those in healthy controls. The area under the ROC curve was 0.92 (95% CI: 0.76-1.00) with a sensitivity of 91.7% and a specificity of 100%. CCR8 levels in patients with ANCA-positive AAV also showed a higher value with statistical significance. The area under the ROC curve was 0.83 (95% CI: 0.79-0.96) with a sensitivity of 75.6% and a specificity of 100%. Immune complex small vessel vasculitis and vasculitis associated with systemic disease did not show the CCR8 elevation. These data indicate that CCR8 is upregulated in pauci-immune glomerulonephritis regardless of serum ANCA levels.

Conclusion

CCR8 could be a useful biomarker in diagnosis of ANCA-negative AAV representing rapidly progressive glomerulonephritis.